The 2017 Global Initiative for Chronic Obstructive Lung Disease Report and Practice Implications for the Respiratory Therapist

References

1. 1.↵
   World Health Organization. Chronic obstructive pulmonary disease (COPD) fact sheet. Geneva, Switzerland; WHO. 2016.
2. 2.↵
   1. Thornton Snider J,
   2. Romley JA,
   3. Wong KS,
   4. Zhang J,
   5. Eber M,
   6. Goldman DP

   . The disability burden of COPD. COPD J Chronic Obstr Pulm Dis 2012;9(5):513–521.

   OpenUrl
3. 3.↵
   1. Guarascio AJ,
   2. Ray SM,
   3. Finch CK,
   4. Self TH

   . The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res 2013;5:235–245.

   OpenUrlPubMed
4. 4.↵
   Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease. 2016.
5. 5.↵
   1. Vestbo J,
   2. Hurd SS,
   3. Agustí AG,
   4. Jones PW,
   5. Vogelmeier C,
   6. Anzueto A,
   7. et al

   . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary (updated 2014). Global Initiative for Chronic Obstructive Lung Disease 2014;163(5):21–26.

   OpenUrl
6. 6.↵
   1. Han MK,
   2. Muellerova H,
   3. Curran-Everett D,
   4. Dransfield MT,
   5. Washko GR,
   6. Regan EA,
   7. et al

   . GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med 2013;1(1):43–50.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Jones PW

   . Health status and the spiral of decline. COPD 2009;6(1):59–63.

   OpenUrlCrossRefWeb of Science
8. 8.↵
   1. Goossens LMA,
   2. Leimer I,
   3. Metzdorf N,
   4. Becker K,
   5. Rutten-van Mölken MPMH

   . Does the 2013 GOLD classification improve the ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial. BMC Pulm Med 2014;14(1):163.

   OpenUrl
9. 9.↵
   1. Kim JH,
   2. Yoon HI,
   3. Oh Y-M,
   4. Lim SY,
   5. Lee J-H,
   6. Kim T-H,
   7. et al

   . Lung function decline rates according to GOLD group in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis Sept 2015;1819.
10. 10.↵
    1. Martinez FJ,
    2. Mannino D,
    3. Leidy NK,
    4. Malley KG,
    5. Bacci ED,
    6. Barr RG,
    7. et al

    . A new approach for identifying patients with undiagnosed chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2017;195(6):748–756.

    OpenUrl
11. 11.↵
    1. Wan ES,
    2. Castaldi PJ,
    3. Cho MH,
    4. Hokanson JE,
    5. Regan EA,
    6. Make BJ,
    7. et al

    . Epidemiology, genetics, and subtyping of preserved ratio impaired spirometry (PRISm) in COPDGene. Respir Res 2014;15(1):89.

    OpenUrl
12. 12.↵
    1. Vaz Fragoso CA,
    2. McAvay G,
    3. Van Ness PH,
    4. Casaburi R,
    5. Jensen RL,
    6. MacIntyre N,
    7. et al

    . Phenotype of normal spirometry in an aging population. Am J Respir Crit Care Med 2015;192(7):817–825.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Mcneill A,
    2. Brose LS,
    3. Calder R,
    4. Hitchman SC,
    5. Hajek P,
    6. H M

    . E-cigarettes: an evidence update: A report commissioned by Public Health England. Public Heal Engl 2015;111.
14. 14.
    1. Hartmann-Boyce J

    1. Hartmann-Boyce J,
    2. McRobbie H,
    3. Bullen C,
    4. Begh R,
    5. Stead LF,
    6. Hajek P

    . Electronic cigarettes for smoking cessation. In: Hartmann-Boyce J, ed. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2016.
15. 15.↵
    1. Schraufnagel DE,
    2. Blasi F,
    3. Drummond MB,
    4. Lam DCL,
    5. Latif E,
    6. Rosen MJ,
    7. et al

    . Electronic cigarettes: a position statement of the forum of international respiratory societies. Am J Respir Crit Care Med 2014;190(6):611–618.

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    1. Wongsurakiat P,
    2. Lertakyamanee J,
    3. Maranetra KN,
    4. Jongriratanakul S,
    5. Sangkaew S

    . Economic evaluation of influenza vaccination in Thai chronic obstructive pulmonary disease patients. J Med Assoc Thai 2003;86(6):497–508.

    OpenUrlPubMed
17. 17.
    1. Nichol KL,
    2. Margolis KL,
    3. Wuorenma J,
    4. Von Sternberg T

    . The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994;331(12):778–784.

    OpenUrlCrossRefPubMedWeb of Science
18. 18.↵
    1. Poole P,
    2. Chacko EE,
    3. Wood-Baker R,
    4. Cates CJ

    . Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2006.
19. 19.↵
    1. Kobayashi M,
    2. Bennett NM,
    3. Gierke R,
    4. Almendares O,
    5. Moore MR,
    6. Whitney CG,
    7. Pilishvili T

    . Intervals between PCV13 and PPSV23 vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2015;64(34):944–947.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Alfageme I

    . Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 2006;61(3):189–195.

    OpenUrlAbstract/FREE Full Text
21. 21.↵
    1. Cranston JM,
    2. Crockett A,
    3. Moss J,
    4. Alpers JH

    . Domiciliary oxygen for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2005.
22. 22.↵
    1. Albert RK,
    2. Au DH,
    3. Blackford AL,
    4. Casaburi R,
    5. Cooper JA Jr.,
    6. Criner GJ,
    7. et al

    . A randomized trial of long-term oxygen for COPD with moderate desaturation. N Engl J Med 2016;375(17):1617–1627.

    OpenUrlPubMed
23. 23.↵
    1. Crim C,
    2. Dransfield MT,
    3. Bourbeau J,
    4. Jones PW,
    5. Hanania NA,
    6. Mahler DA,
    7. et al

    . Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc 2015;12(1):27–34.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Vogelmeier C,
    2. Hederer B,
    3. Glaab T,
    4. Schmidt H,
    5. Rutten-van Mölken MPMH,
    6. Beeh KM,
    7. et al

    . Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011;364(12):1093–1103.

    OpenUrlCrossRefPubMedWeb of Science
25. 25.↵
    1. Barnes PJ

    . New anti-inflammatory targets for chronic obstructive pulmonary disease. Nat Rev Drug Discov. 2013;12(7):543–559.

    OpenUrlCrossRefPubMed
26. 26.↵
    1. Loke YK,
    2. Cavallazzi R,
    3. Singh S

    . Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax 2011;66(8):699–708.

    OpenUrlAbstract/FREE Full Text
27. 27.↵
    1. Johnell O,
    2. Pauwels R,
    3. Löfdahl CG,
    4. Laitinen LA,
    5. Postma DS,
    6. Pride NB,
    7. Ohlsson S V

    . Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. Eur Respir J 2002;19(6):1058–1063.

    OpenUrlAbstract/FREE Full Text
28. 28.↵
    1. Decramer ML,
    2. Chapman KR,
    3. Dahl R,
    4. Frith P,
    5. Devouassoux G,
    6. Fritscher C,
    7. et al

    . Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med 2013;1(7):524–533.

    OpenUrlCrossRefPubMed
29. 29.↵
    1. Saunders T,
    2. Campbell N,
    3. Jason T,
    4. Dechman G,
    5. Hernandez P,
    6. Thompson K,
    7. Blanchard CM

    . Objectively measured steps/day in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. J Phys Act Health 2016;13(11):1275–1283.

    OpenUrl
30. 30.↵
    1. Corhay J-L,
    2. Dang DN,
    3. Van Cauwenberge H,
    4. Louis R

    . Pulmonary rehabilitation and COPD: providing patients a good environment for optimizing therapy. Int J Chron Obstruct Pulmon Dis 2014;9:27–39.

    OpenUrl
31. 31.↵
    1. Ferreira IM,
    2. Brooks D,
    3. White J,
    4. Goldstein R

    . Nutritional supplementation for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd; 2012.
32. 32.↵
    1. Vijayasaratha K,
    2. Stockley RA

    . Reported and unreported exacerbations of COPD: analysis by diary cards. Chest 2008;133(1):34–41.

    OpenUrlCrossRefPubMedWeb of Science
33. 33.↵
    1. Shelledy DC,
    2. Legrand TS,
    3. Gardner DD,
    4. Peters JI

    . A randomized, controlled study to evaluate the role of an in-home asthma disease management program provided by respiratory therapists in improving outcomes and reducing the cost of care. J Asthma 2009;46(2):194–201.

    OpenUrlCrossRefPubMed
34. 34.
    1. Kollef MH,
    2. Shapiro SD,
    3. Clinkscale D,
    4. Cracchiolo L,
    5. Clayton D,
    6. Wilner R,
    7. Hossin L

    . The effect of respiratory therapist-initiated treatment protocols on patient outcomes and resource utilization. Chest 2000;117(2):467–475.

    OpenUrlCrossRefPubMedWeb of Science
35. 35.↵
    1. Werre ND,
    2. Boucher EL,
    3. Beachey WD

    . Comparison of therapist-directed and physician-directed respir care in COPD subjects with acute pneumonia. Respir Care 2015;60(2):151–154.

    OpenUrlAbstract/FREE Full Text
36. 36.↵
    1. Yawn B,
    2. Wollan P,
    3. Textor K,
    4. Yawn R

    . Primary care physicians', nurse practitioners' and physician assistants' knowledge, attitudes and beliefs regarding COPD: 2007 to 2014. Chronic Obs Pulm Dis 2016;3(3):628–635.

    OpenUrl
37. 37.↵
    1. Johns DP,
    2. Walters JAE,
    3. Walters EH

    . Diagnosis and early detection of COPD using spirometry. J Thorac Dis 2014;6(11):1557–1569.

    OpenUrlPubMed
38. 38.↵
    1. Hegewald MJ,
    2. Gallo HM,
    3. Wilson EL

    . Accuracy and quality of spirometry in primary care offices. Ann Am Thorac Soc. 2016;13(12):2119–2124.

    OpenUrl
39. 39.↵
    1. Marks R

    . A review and synthesis of research evidence for self-efficacy-enhancing interventions for reducing chronic disability: implications for health education practice (part II). Health Promot Pract 2005;6(2):148–156.

    OpenUrlCrossRefPubMed
40. 40.↵
    1. Simpson E,
    2. Jones MC

    . An exploration of self-efficacy and self-management in COPD patients. Br J Nurs 2013;22(19):1105–1109.

    OpenUrl
41. 41.↵
    1. Laurin C,
    2. Moullec G,
    3. Bacon SL,
    4. Lavoie KL

    . Impact of anxiety and depression on chronic obstructive pulmonary disease exacerbation risk. Am J Respir Crit Care Med 2012;185(9):918–923.

    OpenUrlCrossRefPubMedWeb of Science
42. 42.↵
    1. Raza T,
    2. Joshi M,
    3. Schapira RM,
    4. Agha Z

    . Pulmonary telemedicine: a model to access the subspecialist services in underserved rural areas. Int J Med Inform 2009;78(1):53–59.

    OpenUrlCrossRefPubMed
43. 43.↵
    1. Stickland M,
    2. Jourdain T,
    3. Wong EYL,
    4. Rodgers WM,
    5. Jendzjowsky NG,
    6. Macdonald GF

    . Using telehealth technology to deliver pulmonary rehabilitation in chronic obstructive pulmonary disease patients. Can Respir J 2011;18(4):216–220.

    OpenUrlCrossRefPubMed